MedTrace Logo

Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms

NCT05438147 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2023-04-26

No results posted yet for this study

Summary

CT-100 is a platform that provides an interactive, software based therapeutic component that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital therapeutics (PDT/DTx), being developed by Click Therapeutics, Inc.

Conditions

Interventions

OTHER

CT-100 DiNaMo

Active Treatment (Study App)

OTHER

Care-as-Usual

Care-As-Usual control

Sponsors & Collaborators

  • Click Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Shaheen Lakhan, MDPhD, FAAN · Click Therapeutics

  • Jacqueline Lutz, PhD · Click Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-13
Primary Completion
2022-09-06
Completion
2022-09-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05438147 on ClinicalTrials.gov